In a historic event this week, Barack Obama became the first American president to visit Cuba in 88 years. The three-day visit was the result of a December 2014 agreement between President Obama and Cuban President Raul Castro to “end an estrangement that began when Cuba’s revolution ousted a pro-American government in 1959.”
Since President Obama announced the beginning of normalization between the U.S. and Cuba, channels are now being opened and opportunities created among businesses and other organizations to access and share information across many fields. As an American company Regenestem, LLC (http://www.regenestem.com) will bring the field of regenerative medicine to the island of Cuba later this year for valuable information sharing at an international level.
Regenestem, a medical practice company focused on adult stem cell therapies and physician training with particular growth in Latin America, is presenting an innovative conference in Cuba devoted to regenerative medicine, in association with the Cuban Institute of Hematology.
The First Inter American Stem Cell Conference will be held October 13-15, at the Palacio de Convenciones, in Havana. The three-day event will explore whether stem cell therapies are ready to become a standard form of treatment. It will also provide a series of hands-on training workshops focusing on some of the stem cell therapies.
Importantly, the conference will highlight renowned international speakers that include:
- Dr Arnold Caplan Case Western University
- Dr Rocky Tuan University or Pittsburgh
- Joshua Hare University of Miami
- Sydney Coleman NYU
- Dr Bob Nerem Georgia Tech
- Dr Jakub Tolar University of Minnesota
- Anthony Atala Wake Forest
- Jeffrey Weiss Florida Atlantic University
- John Salerno
- Charles Mahl
“What better way to build cooperation between the U.S. and Cuba than for professionals in regenerative medicine to come together for some valuable information sharing,” said Ricardo De Cubas, founder and CEO of Regenestem. “Cuba has been a pillar in this field for decades – and it is time that the doors be opened for forward-thinking physicians and researchers from around the world be given the opportunity to present their knowledge and expertise for the benefit of the global medical community.”
As examples of Cuban breakthroughs, medical research facilities in the U.S. and Cuba struck a deal last year to allow clinical trials of Cimavax, an effective lung cancer vaccine developed in Cuba, which stops tumors from growing. In addition, Heberprot-P was developed in 2006 by a Cuban research center to prevent the limbs of diabetic patients from being amputated. Diabetic wound specialists say Heberprot-P may be the best chance to save the lives and limbs of tens of thousands of Americans.
De Cubas said the inspiration for this conference came from his late father. Dr. Luis A. De Cubas practiced medicine in the U.S. from 1966 to 2005 after fleeing from Cuba in March of 1966. De Cubas was a renowned pediatrician in both Minneapolis and Miami.
For more information on the conference or to register, call (305) 224-1858. Registration and travel arrangements must be made by July 1.
About Regenestem, LLC
Regenestem (http://www.regenestem.com) is an international medical practice company focused on providing comprehensive solutions involving adult stem cell treatments and research. The firm has assembled a talented staff of medical specialists – professionals trained in the latest cutting-edge procedures and protocols in cellular medicine. Regenestem is certified for the medical tourism market – and staff physicians are board-certified or board-eligible, providing services in more than 10 specialties. Regenestem investigates, shares, utilizes and integrates the latest protocols in the adult stem cell arena to deliver the best medical solutions to its patients. The brand also includes a membership association of regenerative medicine clinics, a training and education division, and an online store.
BioInformant is the first and only market research firm to specialize exclusively in the stem cell industry. BioInformant research has been cited by major news outlets that include the Wall Street Journal, Nature Biotechnology, CBS News, Medical Ethics, and the Center for BioNetworking. Serving Fortune 500 leaders that include GE Healthcare, Pfizer, Goldman Sachs, and Becton Dickinson, BioInformant is your global leader in stem cell industry data.
Click here to view our global strategic reports for the stem cell industry.
Tell Us What You Think!